Nasdaq:ALT

All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions in liver fat, with a 68.5% relative reduction in liver fat content in subjects receiving 1.8 mg dose at 12 weeks of…

GAITHERSBURG, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022…

GAITHERSBURG, Md., April 01, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the…

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster…

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following…

AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteersAltimmune will discontinue further development of AdCOVID and focus its resources on its ongoing obesity and liver programsAltimmune also…